BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 23314822)

  • 1. Re-irradiation with and without bevacizumab as salvage therapy for recurrent or progressive high-grade gliomas.
    Hundsberger T; Brügge D; Putora PM; Weder P; Weber J; Plasswilm L
    J Neurooncol; 2013 Mar; 112(1):133-9. PubMed ID: 23314822
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcomes of salvage fractionated re-irradiation combined with bevacizumab for recurrent high-grade gliomas that progressed after bevacizumab treatment*.
    Yonezawa H; Ohno M; Igaki H; Miyakita Y; Takahashi M; Tamura Y; Shima S; Matsushita Y; Ichimura K; Narita Y
    Jpn J Clin Oncol; 2021 Jul; 51(7):1028-1035. PubMed ID: 33959771
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-dose salvage re-irradiation for recurrent/progressive adult diffuse glioma: healing or hurting?
    Gupta T; Maitre M; Maitre P; Goda JS; Krishnatry R; Chatterjee A; Moiyadi A; Shetty P; Epari S; Sahay A; Patil V; Jalali R
    Clin Transl Oncol; 2021 Jul; 23(7):1358-1367. PubMed ID: 33528810
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of stereotactic radiosurgery and adjuvant bevacizumab in patients with recurrent malignant gliomas.
    Cuneo KC; Vredenburgh JJ; Sampson JH; Reardon DA; Desjardins A; Peters KB; Friedman HS; Willett CG; Kirkpatrick JP
    Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):2018-24. PubMed ID: 21489708
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Salvage fractionated stereotactic re-irradiation (FSRT) for patients with recurrent high grade gliomas progressed after bevacizumab treatment.
    Shi W; Blomain ES; Siglin J; Palmer JD; Dan T; Wang Y; Werner-Wasik M; Glass J; Kim L; Bar Ad V; Bhamidipati D; Evans JJ; Judy K; Farrell CJ; Andrews DW
    J Neurooncol; 2018 Mar; 137(1):171-177. PubMed ID: 29235052
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A multi-center prospective study of re-irradiation with bevacizumab and temozolomide in patients with bevacizumab refractory recurrent high-grade gliomas.
    Dixit KS; Sachdev S; Amidei C; Kumthekar P; Kruser TJ; Gondi V; Grimm S; Lukas RV; Nicholas MK; Chmura SJ; Fought AJ; Mehta M; Raizer JJ
    J Neurooncol; 2021 Dec; 155(3):297-306. PubMed ID: 34689306
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Retrospective Review of Re-irradiating Patients' Recurrent High-grade Gliomas.
    Klobukowski L; Falkov A; Chelimo C; Fogh SE
    Clin Oncol (R Coll Radiol); 2018 Sep; 30(9):563-570. PubMed ID: 29891395
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multicenter, Phase 1, Dose Escalation Study of Hypofractionated Stereotactic Radiation Therapy With Bevacizumab for Recurrent Glioblastoma and Anaplastic Astrocytoma.
    Clarke J; Neil E; Terziev R; Gutin P; Barani I; Kaley T; Lassman AB; Chan TA; Yamada J; DeAngelis L; Ballangrud A; Young R; Panageas KS; Beal K; Omuro A
    Int J Radiat Oncol Biol Phys; 2017 Nov; 99(4):797-804. PubMed ID: 28870792
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 3D conformal radiotherapy and cisplatin for recurrent malignant glioma.
    VanderSpek L; Fisher B; Bauman G; Macdonald D
    Can J Neurol Sci; 2008 Mar; 35(1):57-64. PubMed ID: 18380278
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bevacizumab use for recurrent high-grade glioma at McGill University Hospital.
    Sahebjam S; Garoufalis E; Guiot MC; Muanza T; Del Maestro R; Petrecca K; Sharma R; Kavan P
    Can J Neurol Sci; 2013 Mar; 40(2):241-6. PubMed ID: 23419575
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of children with recurrent high grade gliomas with a bevacizumab containing regimen.
    Parekh C; Jubran R; Erdreich-Epstein A; Panigrahy A; Bluml S; Finlay J; Dhall G
    J Neurooncol; 2011 Jul; 103(3):673-80. PubMed ID: 21038110
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Re-Irradiation for Recurrent Gliomas: Treatment Outcomes and Prognostic Factors.
    Lee J; Cho J; Chang JH; Suh CO
    Yonsei Med J; 2016 Jul; 57(4):824-30. PubMed ID: 27189273
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas.
    Gutin PH; Iwamoto FM; Beal K; Mohile NA; Karimi S; Hou BL; Lymberis S; Yamada Y; Chang J; Abrey LE
    Int J Radiat Oncol Biol Phys; 2009 Sep; 75(1):156-63. PubMed ID: 19167838
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Timing of re-irradiation in recurrent high-grade gliomas: a single institution study.
    Zemlin A; Märtens B; Wiese B; Merten R; Steinmann D
    J Neurooncol; 2018 Jul; 138(3):571-579. PubMed ID: 29520609
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term efficacy and toxicity of bevacizumab-based therapy in children with recurrent low-grade gliomas.
    Hwang EI; Jakacki RI; Fisher MJ; Kilburn LB; Horn M; Vezina G; Rood BR; Packer RJ
    Pediatr Blood Cancer; 2013 May; 60(5):776-82. PubMed ID: 22976922
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bevacizumab treatment of symptomatic pseudoprogression after boron neutron capture therapy for recurrent malignant gliomas. Report of 2 cases.
    Miyatake S; Furuse M; Kawabata S; Maruyama T; Kumabe T; Kuroiwa T; Ono K
    Neuro Oncol; 2013 Jun; 15(6):650-5. PubMed ID: 23460324
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcome after bevacizumab clinical trial therapy among recurrent grade III malignant glioma patients.
    Reardon DA; Herndon JE; Peters K; Desjardins A; Coan A; Lou E; Sumrall A; Turner S; Sathornsumetee S; Rich JN; Boulton S; Lipp ES; Friedman HS; Vredenburgh JJ
    J Neurooncol; 2012 Mar; 107(1):213-21. PubMed ID: 21997879
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of salvage reirradiation for malignant gliomas that progress on bevacizumab.
    Torcuator RG; Thind R; Patel M; Mohan YS; Anderson J; Doyle T; Ryu S; Jain R; Schultz L; Rosenblum M; Mikkelsen T
    J Neurooncol; 2010 May; 97(3):401-7. PubMed ID: 19838627
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Large volume reirradiation as salvage therapy for glioblastoma after progression on bevacizumab.
    Magnuson W; Ian Robins H; Mohindra P; Howard S
    J Neurooncol; 2014 Mar; 117(1):133-9. PubMed ID: 24469853
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiangiogenic therapy for high-grade glioma.
    Khasraw M; Ameratunga MS; Grant R; Wheeler H; Pavlakis N
    Cochrane Database Syst Rev; 2014 Sep; (9):CD008218. PubMed ID: 25242542
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.